Britain told to track transgenic trade
London The international movement of cloned and genetically modified animals should be monitored to prevent smuggling, maintain consumer choice and protect the environment, the British government has been told.
The Agriculture and Environment Biotechnology Commission (AEBC), a UK government advisory body, says that the arrangements must be in place before the production and trade of transgenic animals becomes widespread. Current movement regulations do not require exporters to state if animals or reproductive material have been modified or cloned.
Animals and Biotechnology, published on 3 September, says the Cartagena Protocol on Biosafety could provide a suitable starting point. The protocol requires countries exporting transgenic animals or plants to obtain the informed consent of importing countries, but it has not yet been ratified by enough countries to enter into force and does not cover cloned animals or embryos.
Book reveals short measure but still the metre rules London A new book will bring satisfaction to the many Britons and Americans who are reluctant to use the metric system -the metre is apparently shorter than it should be.
The metre was first defined as one tenmillionth of the distance from the Pole to the Equator. But in The Measure of All Things (Free Press/Little, Brown), science historian Ken Alder claims that the eighteenth-century French astronomers given the task of working out the measurement bungled their calculations.As a result, the metre is 0.2 mm short of its original definition.
According to Alder, expedition log books show that one of the astronomers, Pierre Françoise André Méchain, discovered that two of his measurements made from the same place did not agree. Letters show he was driven to the brink of madness by his decision to conceal the error. He eventually died of malaria on a trip to correct the measurement.
The second astronomer, Jean Baptiste Joseph Delambre, was aware of the cover-up and admitted in the logs that:"I have not told the public what it does not need to know."
Correction The recent News Feature on immune tolerance (Nature 418, 364-366; 2002) stated that researchers at Dartmouth Medical School had halted a clinical trial of a monoclonal antibody to treat multiple sclerosis when one patient developed blood clots. In fact, the patient who developed clots was enrolled in another trial, which was investigating whether the same antibody could ease symptoms of Crohn's disease.
